Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
NCT02282358 · Memorial Sloan Kettering Cancer Center · PHASE1/PHASE2 · terminated · last registry update 2024-03-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of accrual” | – | Registry record, Memorial Sloan Kettering Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-07Results posted on the registry: Spanish Lung Cancer Group, Vorinostat plus Erlotinib (NCT00503971)
- 2025-03-07Also stopped (terminated): Spanish Lung Cancer Group, Vorinostat plus Erlotinib (NCT00503971)
- 2025-02-24Also stopped (terminated): Australian & New Zealand Children's Haematology/Oncology Group, Panobinostat (NCT04897880)
- 2025-02-10Also stopped (terminated): Biodexa Pharmaceuticals, MTX110 (NCT05324501)
- 2025-01-24Results posted on the registry: Italfarmaco, Givinostat (NCT05860114)
- 2025-01-06Results posted on the registry: Italfarmaco, Givinostat 10 mg/mL + Midazolam 1mg/ml IV (NCT05492318)
- 2024-11-18Results posted on the registry: Nabil Adra, Pembrolizumab + Vorinostat (NCT02619253)
- 2024-11-18Results posted on the registry: Italfarmaco, Givinostat + Placebo (NCT03238235)
- 2024-11-12Also stopped (terminated): National Cancer Institute (NCI), Carboplatin + Paclitaxel (NCT01413750)
- 2024-11-07Results posted on the registry: Memorial Sloan Kettering Cancer Center, Romidepsin + Lenalidomide (NCT01755975)
- 2024-10-15Also stopped (withdrawn): Virginia Commonwealth University, Vorinostat Oral Capsule Group 1 + Vorinostat Oral Capsule Group 2 (NCT03263533)
- 2024-10-01Results posted on the registry: National Cancer Institute (NCI), Entinostat + Pembrolizumab (NCT02936752)
- 2024-09-03Results posted on the registry: Roberto Pili, Entinostat + Nivolumab (NCT03552380)
- 2024-09-03Also stopped (terminated): Roberto Pili, Entinostat + Nivolumab (NCT03552380)
- 2024-08-22Results posted on the registry: M.D. Anderson Cancer Center, Vorinostat + Isotretinoin (NCT00555399)
- 2024-08-22Also stopped (terminated): M.D. Anderson Cancer Center, Vorinostat + Isotretinoin (NCT00555399)
- 2024-08-22Results posted on the registry: Columbia University, RomiDEPsin 10 MG/M2 + Oral 5-Azacitidine 100 MG (NCT01998035)
- 2024-08-22Also stopped (terminated): Columbia University, RomiDEPsin 10 MG/M2 + Oral 5-Azacitidine 100 MG (NCT01998035)
- 2024-08-19Phase 3 first posted: Corvus Pharmaceuticals, Inc., Soquelitinib + Belinostat (NCT06561048)
- 2024-08-05Also stopped (withdrawn): National Cancer Institute (NCI), Nivolumab + Entinostat (NCT05898828)
- 2024-07-12Results posted on the registry: pharmaand GmbH, Panobinostat Capsules + Bortezomib Injection (NCT02654990)
- 2024-07-08Results posted on the registry: Celgene, Azacitidine + Romidepsin (NCT03703375)
- 2024-06-06Also stopped (terminated): Abdullah Khan, Bortezomib + Daratumumab and Hyaluronidase-fihj (NCT04956302)
- 2024-05-03Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Azacitidine + Entinostat (NCT01928576)
- 2024-04-25Results posted on the registry: Pediatric Brain Tumor Consortium, LBH589 (NCT02717455)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision